NeuroClnx at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
NeuroClnx takes part in 2 sessions at CTAD 2026 in Boston. Its program draws on its experience as a site in the AHEAD 3-45 programme. Its work covers blood test eligibility, APOE genotyping and amyloid confirmation, and the limits of cognitive prescreening for amyloid enrichment.
| Organization | CTAD 2026 Attendance |
|---|---|
NeuroClnx Glasgow, UK | |
UK clinical research site network with clinics in Glasgow and Warrington running Alzheimer's and other neurology trials. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue |
Instantly find 20 buyers from NeuroClnx
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction